Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2025-05-20 00:00:00 ET · period of report 2025-05-16 · accession 0001213900-25-046088 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-20 | 2025-05-16 | RLMD | Kelly Paul Edward | COO, Dir | P - Purchase | $0.43 | +200.0K | 412.3K | +94% | +$86.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-16 | P | A | 200,000 | $0.43 | 412,295 | D | — | — | (F1) The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. (F2) Purchase prices range from $0.4071 to $0.4498 per share, inclusive. |